A phase I trial of TL-532 for treatment of non-muscle-invasive bladder cancer
Latest Information Update: 03 Jun 2022
At a glance
- Drugs TL-532 (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- Sponsors TOLLYS SAS
Most Recent Events
- 03 Jun 2022 New trial record